Find a story

Search Spins

Search titles, summaries, and missing voices across published articles — press releases, announcements, and media coverage.

15 results for “biotech”

SPIN Processed News Frame: The Cushion

Icon inks Anthropic deal to deploy Claude into clinical trials - Fierce Biotech

Icon, a clinical research organization, has partnered with Anthropic to integrate Claude AI into clinical trial operations, aiming to improve trial design, documentation, and regulatory compliance.

Spin 85% Claim Present in Source AI Risk High
Google News: Anthropic

Aug 5, 2026

SPIN Processed Press Release Frame: The Hype

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

FibroBiologics announced it has dosed the first patients in a phase 1/2 clinical trial for CYWC628, its lead wound care candidate targeting diabetic foot ulcers, and expects interim results in the second half of 2026.

Spin 75% Claim Present in Source AI Risk Moderate
PR Newswire Technology

Aug 1, 2026

SPIN Processed Press Release Frame: The Stampede

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed

A press release from MindWalk Holdings Corp. (NASDAQ: HYFT) announces its appearance at a major computing event to signal strategic positioning in AI-driven drug discovery, though no specific product launch, clinical validation, or technical milestone is disclosed.

Spin 82% Claim Present in Source AI Risk Moderate
PR Newswire Financial Services

Jul 24, 2026

SPIN Processed News Frame: The Shield

Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first

A U.S. biotech firm chose to list in Hong Kong before Wall Street, reflecting a strategic pivot toward Asian capital markets and Chinese pharma collaboration.

Spin 65% Needs Evidence AI Risk Moderate
CNBC Technology

Jul 22, 2026

SPIN Processed News Frame: The Fog

Biotech IPO Gains Crush AI Listings With Standout 55% Return - Bloomberg.com

Biotech initial public offerings outperformed AI-related IPOs in the reporting period, delivering a 55% average return compared to weaker returns from AI listings.

Spin 45% Needs Evidence AI Risk Moderate
Bloomberg Fintech via Google News

Jul 21, 2026

SPIN Processed Press Release Frame: The Stampede

Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

Krystal Biotech, a biotechnology company, is being added to the S&P MidCap 400 index, replacing a homebuilding firm — a routine index rebalancing decision reflecting market capitalization and liquidity criteria.

Spin 75% Claim Present in Source AI Risk Moderate
PR Newswire Financial Services

Jul 21, 2026

SPIN Processed News Frame: The Hype

Kalshi is offering wagers on the outcomes of late-stage clinical drug trials and regulatory decisions, launching a pilot of 13 new biotech contracts (Madison Muller/Bloomberg)

Kalshi, a prediction market platform, launched a pilot offering financial wagers on outcomes of late-stage clinical drug trials and regulatory decisions — introducing speculative trading into high-stakes biomedical decision-making.

Spin 75% Claim Present in Source AI Risk Moderate
Techmeme

Jul 17, 2026

SPIN Processed News Frame: The Hype

Summit sells failed antibiotic to OpenAI-backed startup in $105M deal - Fierce Biotech

Summit Therapeutics sold rights to a failed antibiotic candidate to an OpenAI-backed startup for $105 million, signaling a strategic pivot from clinical failure to AI-driven drug repurposing.

Spin 75% Claim Present in Source AI Risk High
Google News: OpenAI

Jul 14, 2026

SPIN Processed News Frame: The Halo

This Biotech Lets Rare-Disease Families Invest In Its Gene Therapy - Forbes

A biotech company has created a novel investment model allowing families affected by rare diseases to directly fund and participate in the development of gene therapies targeting those conditions.

Spin 78% Needs Evidence AI Risk Moderate
Forbes AI / SaaS via Google News

Jul 14, 2026

SPIN Processed News Frame: The Stampede

Reed Jobs would rather talk about curing cancer than his last name

Reed Jobs's biotech venture firm Yosemite has grown to 17 people and integrated AI deeply into its drug discovery workflow amid a wave of expiring blockbuster drug patents, positioning itself to capitalize on newly opened therapeutic opportunities.

Spin 70% Claim Present in Source AI Risk Moderate
TechCrunch

Jul 12, 2026

SPIN Processed News Frame: The Shield

U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China - WSJ

U.S. biotechnology firms are increasing secrecy around R&D and manufacturing processes to prevent intellectual property theft by Chinese competitors, reflecting a strategic shift in response to perceived IP vulnerabilities.

Spin 75% Source-Supported AI Risk Moderate Needs Evidence
WSJ Banking / Fintech via Google News

Jul 11, 2026

SPIN Processed News Frame: The Stampede

I spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learned - STAT

Anthropic's CEO discussed speculative applications of AI in biotech during an interview with STAT, highlighting potential future impacts without reporting on concrete deployments, products, or verified outcomes.

Spin 75% Claim Present in Source AI Risk Moderate
Google News: Anthropic

Published Jul 6, 2026 · Analyzed Jul 8, 2026

SPIN Processed Press Release Frame: The Cushion

Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence

Nona Biosciences, a biotech company focused on AI-enabled biotherapeutic discovery, appointed Dr. Peng Wang as COO to strengthen operational execution amid platform development and scaling efforts.

Spin 70% Claim Present in Source AI Risk High
PR Newswire Technology

Published Jul 3, 2026 · Analyzed Jul 6, 2026

SPIN Processed Press Release Frame: The Hype

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Northwest Biotherapeutics announces scientific presentation on propensity score matching at British Neuro-Oncology Society Annual Meeting.

Spin 70% Claim Present in Source AI Risk Moderate
PR Newswire Technology

Published Jul 2, 2026 · Analyzed Jul 5, 2026

SPIN Processed News Frame: The Hype

This Biotech Startup Just Raised $255 Million To Make Its AI-Designed Drug A Reality - Forbes

A biotech startup secured $255 million in funding to advance an AI-designed drug candidate into clinical development, signaling investor confidence in AI-driven drug discovery.

Spin 75% Claim Present in Source AI Risk High
Forbes AI / SaaS via Google News

Published Jun 22, 2021 · Analyzed Jul 7, 2026